Skip to main content

Table 3 Multivariate analysis of clinical pathology and prognosis of 2917 BC patients with bone metastasis

From: Impact of surgery on survival in breast cancer with bone metastases only: a SEER database retrospective analysis

Variables Regression coefficient Standard error P-value HR 95%CI
Marital      
Married Reference     
Unmarried 0.193 0.056 0.001 1.213 1.087–1.354
Age      
 ≤ 35 Reference     
35 < age < 60 − 0.07 0.147 0.635 0.933 0.700–1.243
 ≥ 60 0.258 0.147 0.08 1.294 0.970–1.727
Race      
White Reference     
Black 0.267 0.071  < 0.001 1.306 1.135–1.502
Other 0.001 0.113 0.995 1.001 0.802–1.248
Histology      
IDC Reference     
Non-IDC 0.331 0.065  < 0.001 1.392 1.225–1.583
Primary surgery      
Non-operation Reference     
Operation − 0.644 0.059  < 0.001 0.525 0.467–0.590
Chemotherapy      
Yes Reference     
No 0.383 0.061  < 0.001 1.467 1.302–1.653
T stage      
T1 Reference     
T2 0.116 0.091 0.2 1.123 0.940–1.341
T3 0.247 0.099 0.013 1.28 1.054–1.555
T4 0.321 0.093 0.001 1.379 1.149–1.654
Radiation      
Yes Reference     
No − 0.011 0.055 0.849 0.99 0.888–1.103
Grade      
1 Reference     
2 0.234 0.1 0.02 1.263 1.038–1.538
3–4 0.583 0.105  < 0.001 1.791 1.459–2.199
HER2      
Positive Reference     
Negative 0.571 0.082  < 0.001 1.771 1.508–2.079
ER      
Positive Reference     
Negative 0.589 0.095  < 0.001 1.802 1.496–2.170
PR      
Positive reference     
Negative 0.442 0.073  < 0.001 1.556 1.348–1.797
Subtype      
ER + /HER2− Reference     
ER + /HER2 +  − 0.243 0.091 0.007 0.785 0.657–0.937
HER2 +  − 2.024 0.353  < 0.001 0.132 0.066–0.264
TNBC − 0.547 0.322 0.089 0.579 0.308–1.088
Surgical mode      
Non-operation Reference     
BCS − 0.93 0.099  < 0.001 0.394 0.325–0.478
Mastectomy − 0.702 0.108  < 0.001 0.496 0.401–0.613
Radical mastectomy − 0.488 0.071  < 0.001 0.614 0.534–0.706
  1. ER estrogen receptor, PR progesterone receptor, Her-2 human epidermal growth factor receptor 2, IDC infiltrating ductal carcinoma, BCS breast conserving surgery, TNBC triple-negative breast cancer